Savara Inc. (NASDAQ:SVRA – Get Free Report) has been given an average rating of “Moderate Buy” by the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $10.1429.
SVRA has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Savara in a research report on Monday, March 16th. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. William Blair set a $10.00 price objective on Savara in a report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Finally, Oppenheimer began coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price for the company.
Get Our Latest Stock Report on SVRA
Savara Price Performance
Savara (NASDAQ:SVRA – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Research analysts forecast that Savara will post -0.57 earnings per share for the current year.
Institutional Investors Weigh In On Savara
Several hedge funds have recently made changes to their positions in SVRA. Prudential Financial Inc. purchased a new position in Savara during the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets lifted its holdings in shares of Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP acquired a new stake in shares of Savara in the second quarter worth $33,000. Russell Investments Group Ltd. boosted its position in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after buying an additional 9,463 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of Savara during the third quarter valued at $44,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.
Savara Company Profile
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Featured Articles
- Five stocks we like better than Savara
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
